STAT+: Pharmalittle: Mid-year price hikes for U.S. drugs reaches new heights; onetime biotech CEO Vivek Ramaswamy sparks debate at GOP debate
Good morning, Pharmalittle readers. Reporter Andrew Joseph here filling in for Ed from STAT’s London…
Category: pharmalittle
STAT+: Pharmalittle: U.S. appeals court upholds limits to abortion pill; ‘knock-off’ Ozempic thrives on ‘bogus’ website
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Pharmalittle: Amazon Pharmacy offers insulin discounts; DOJ blasts industry attempt to delay Medicare drug-price talks
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: Pharmalittle: White House drug-shortage panel is MIA with lawmakers; Ultragenyx sued by Lacks family
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Supreme Court halts Purdue bankruptcy plan; what to know about compounded obesity drugs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Genentech weighs delaying cancer therapy after drug pricing law; Novo continues to restrict supplies of low-dose Wegovy
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Pharmalittle: Wegovy heart study has docs seeing new possibilities; drugmakers file more ‘continuation’ patents that sideline generic rivals
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Novo’s Wegovy obesity drug lowers cardiovascular risk in key trial; Nektar accuses Lilly of ‘misconduct’ in development deal
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Pharmalittle: FDA OKs Sage drug for postpartum depression; major U.S. health systems to offer Alzheimer’s drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: White House drug-shortage task force brainstorms fixes; U.S. pharma layoffs are ballooning
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Patients brace for insurance decisions on weight loss drugs; Indian authorities find multiple problems at pharma plants
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Pharmalittle: Some employers cut insurance coverage for weight loss drugs; U.S. urges ADHD pill makers to boost production
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Pharmalittle: Medicare looks to improve Alzheimer’s care but sidesteps drug prices; CVS to cut 5,000 jobs
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Pharmalittle: House Republicans and Democrats duel over drug shortages; FDA approves second over-the-counter naloxone
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pharma hopes reformulated drugs will skirt Medicare negotiations; Biogen to acquire Reata for $7.3 billion
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: House Dems push new bill for Medicare drug negotiations; WHO leaves obesity drugs off essential medicines list
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: State Medicaid programs seek discounts for Wegovy; congressional PBM bills work around the fringes
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Pharmalittle: Three big drugmakers spent less on lobbying after leaving PhRMA; EMA reviews CRO over data concerns
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Sanders wants to replace drug patents with prizes for innovation; FDA approves an anthrax vaccine
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Health care mergers facing tougher antitrust scrutiny; tornado hits Pfizer plant and more shortages may result
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: J&J is third drugmaker to sue over Medicare negotiations; Teva faces trial over Medicare kickbacks
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
.jpg)
STAT+: Pharmalittle: Data confirm benefits and risks of Lilly Alzheimer’s drug; Medicare aims to pay hospitals to stockpile essential drugs
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: Alzheimer’s diagnosis revamp embraces rating scale similar to cancer; FTC seeks info on Pfizer-Seagen deal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: FDA grants full approval to Alzheimer’s drug; Sanders blocks NIH nominee over drug costs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Next big hope for Alzheimer’s might not help most Black patients; drugmakers ask Supreme Court to toss terrorism-support ruling
Top of the morning to you, and a fine one it is. Cool breezes and…
.jpg)
STAT+: Pharmalittle: Novo Nordisk spent $11 million on doctors to promote Ozempic and similar drugs; China offers foreign drugmakers an olive branch
Good morning, everyone, and nice to see you again after an extended holiday break, at…
STAT+: Pharmalittle: FDA approves BioMarin gene therapy for hemophilia A; former Pfizer worker charged with insider trading
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Drug-wholesaler owner indicted for alleged role in diverting HIV medicines; Catalent linked to Regeneron drug rejection
Top of the morning to you. A delicious cool breeze and shiny sun are hovering…
STAT+: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Nearly half of U.S. adults would spend $100 a month for weight loss drugs; Pfizer scraps an obesity pill
Good morning, everyone. and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Novo Nordisk sues spas, clinics over compounded Wegovy; top lobbyist leaves PhRMA
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Pharmalittle: Opaque conflicts permeate prescription drug benefits; Sanofi prevails in Zantac arbitration
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: Bristol Myers sues HHS over Medicare drug negotiations; Lilly reports new shortages of Mounjaro diabetes drug
Good morning, everyone, and welcome to another working week, albeit an abbreviated one for many,…
STAT+: Pharmalittle: FDA cites another troubled plant at company contributing to cancer drug shortages; USDA to push food producers over antibiotic claims
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA panel to review Alzheimer’s treatment; FDA advisers back approval of RSV drug for children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits
Rise and shine, everyone, another busy day is on the way, although the smoky covering…
STAT+: Pharmalittle: U.K. launches pilot to expand access to weight loss drugs; European Union approves RSV vaccine
Top of the morning to you, and a fine one it is. Well, sort of….
STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: AstraZeneca lung cancer drug halves death risk; 400 Grail patients incorrectly told they may have cancer
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s drug coverage policy; Pfizer says antibiotic combo can treat some superbugs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the back half…
STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment
Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with…
STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis
Oh, what a beautiful morning. Yes, this is a cliché, but the saying is apt,…
STAT+: Pharmalittle: Biden administration proposes yearly audit for costliest Medicaid drugs; few at high risk of HIV take prevention pills
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: AstraZeneca plans to ‘love’ China’s Communist Party; U.S. Supreme Court rules against Amgen in patent case
And so, another working week will soon draw to a close. Not a moment too…